|
Jun 16
|
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
|
|
Jun 15
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
|
|
Jun 13
|
Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Video: Trump's Drug Pricing Order Threatens Investment, Says Roche CEO
|
|
May 29
|
The Zacks Analyst Blog Highlights Alphabet, Bank of America, Roche, Village Super Market and Aware
|
|
May 28
|
Top Analyst Reports for Alphabet, Bank of America & Roche
|
|
May 28
|
Mapping out opportunities to reduce emissions in clinical trials
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 26
|
Roche and Broad Clinical Labs to partner on advancing SBX technology
|
|
May 25
|
Tandem Diabetes and Roche Reach a Patent Settlement
|
|
May 24
|
Tandem Diabetes, Roche enter patent settlement agreement
|
|
May 23
|
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
|
|
May 23
|
Genentech to onshore US manufacturing amid rising drug pricing tensions
|
|
May 23
|
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
|
|
May 23
|
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
|
|
May 23
|
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
|
|
May 23
|
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
|
|
May 23
|
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
|